Navigation Links
Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV
Date:5/8/2012

about 35 to 75 minutes. For optimal effect, Intermezzo should not be administered with or immediately after a meal. 

Important Safety Information
Intermezzo is contraindicated in patients with known hypersensitivity to zolpidem. Observed reactions with zolpidem include anaphylaxis and angioedema.

Co-administration with Intermezzo and other CNS depressants increases the risk of CNS depression. Intermezzo should not be taken with alcohol. The use of Intermezzo with other sedative-hypnotics (including other zolpidem products) at bedtime or the middle of the night is not recommended.

The risk of next-day driving impairment (and psychomotor impairment) is increased if Intermezzo is taken with less than four hours of bedtime remaining; if a higher than recommended dose is taken; if co-administered with other CNS depressants; or co-administered with other drugs that increase the blood levels of zolpidem. A small negative effect on SDLP (standard deviation of lateral position, a measure of driving impairment) may remain in some patients four hours after the 1.75 mg dose in women, and after the 3.5 mg dose in men, such that a potential negative effect on driving cannot be completely excluded.

Additional Important Safety Information is presented below.

About Intermezzo Clinical Studies
The safety and efficacy of Intermezzo was evaluated in two randomized, double-blind, placebo-controlled studies in patients with insomnia characterized by difficulty returning to sleep after a middle-of-the-night awakening. Patients met the diagnosis for primary insomnia as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) and had at least 3 prolonged middle-of-the-night awakenings per week of at least 30 minutes in duration.

In a four-week outpatient study in 295 adult patients aged 18 to 64 years (201 females, 94 males), Intermezzo 3.5 mg or placebo was taken on an as-needed basis followin
'/>"/>

SOURCE Purdue Pharma L.P.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Worldwide Multicenter Experiences with CardioFocus HeartLight® EAS to be Presented at Heart Rhythm 2012
2. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
3. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
4. Enanta Announces Positive Phase 2 Results From Interferon-Free Combination Studies with ABT-450 for Hepatitis C Treatment to be Presented at EASL
5. 12 Month TRAM Data Collated Using TIGR® Matrix Surgical Mesh in a Randomized Controlled Study Presented at MAPACS 2012
6. Johnson & Johnson to Provide Webcast Presentation of XARELTO® (rivaroxaban) Phase 3 Clinical Data Presented at the American College of Cardiologys Annual Scientific Sessions
7. Frost & Sullivan New Product Innovation Award Presented to Brainsway for Its Deep Transcranial Magnetic Stimulation (dTMS) Device
8. Delcath CHEMOSAT Presented as Innovative Treatment for Liver Metastases by European Institute of Oncology
9. Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI): Phase III Data on Bayers Investigational Compound Regorafenib (BAY 73-4506) in Patients with Metastatic Colorectal Cancer to be Presented as Late Breaking Or
10. nContacts Cardiac Ablation Technology to be Presented in Two Noteworthy Posters at Boston Atrial Fibrillation Symposium 2012
11. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML Presented at the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... -- Actavis, Inc. (NYSE: ACT ) today announced that ... and Exchange Commission (SEC) a registration statement on Form S-4 ... plc (NASDAQ: WCRX ), which included a ... (the "Form S-4"). As previously announced on May ... into a definitive agreement pursuant to which Actavis will acquire ...
(Date:6/18/2013)... , June 18, 2013 Royal Philips ... was named Overall Performance Leader in Imaging Equipment in ... Infrastructure report. Philips also received Best in KLAS and ... products: Ingenuity Core 128 Computed Tomography (CT), Ingenia ... PageWriter TC70 cardiograph. The annual Best in KLAS Awards: ...
(Date:6/18/2013)... , June 18, 2013  Millennium HealthCare ... has entered into an exclusive 25-year Supply and ... with eWellness Corporation ("EWC") for its Distance Monitored ... to use physical therapy program is a critical ... cardiovascular disease," said Chris Amandola , president, ...
Breaking Medicine Technology:Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 3Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 4Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 5Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 6Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 7Philips Named 2013 Overall Performance Leader In Imaging Equipment By KLAS 2Millennium HealthCare Signs Exclusive Distribution Agreement with eWellness Corporation for Northeast and Mid-Atlantic Regions 2Millennium HealthCare Signs Exclusive Distribution Agreement with eWellness Corporation for Northeast and Mid-Atlantic Regions 3
... Therapeutics, Inc. today,announced completion of a Phase ... kappa opioid agonist, CR845, under development for ... drug candidate was safe and,well-tolerated after intravenous ... expected to be associated with clinical analgesic ...
... CyberKnife System at Oklahoma ... CyberKnife Center, ... global leader in the field of radiosurgery,announced today that the first ... was recently,installed at the Oklahoma CyberKnife, LLC in Tulsa, OK. The ...
Cached Medicine Technology:Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845 2New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times 2New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times 3New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times 4
(Date:6/19/2013)... release is available in Spanish . ... of neglected diseases, it goes by the name of the ... was devoted to conditions that accounted for 90 per cent ... imbalance that the Drugs for Neglected Diseases initiative (DNDi) came ... the organization has been granted the BBVA Foundation Frontiers of ...
(Date:6/19/2013)... View Terrace, California (PRWEB) June 19, 2013 ... announce the launch of new websites. These online links are ... like Organic Septic Tank cleaner, Organic Odor Control Mold Magician ... completely safe for fish and animals in the water as ... harmful waste and sludge buildup that can accumulate at the ...
(Date:6/19/2013)... Researchers at Moffitt Cancer Center and colleagues at Louisiana ... prostate cancers that require immediate therapy. It relies on ... The goal is to better predict a prostate cancer,s ... study was published in the online journal PLOS ... prostate cancer accounts for 20 percent of all cancers ...
(Date:6/19/2013)... AZ (PRWEB) June 19, 2013 Guests at ... healthy, wealthy and wise even if they don’t go to ... does require some early thought. , Crafty ... when they take advantage of the pet-friendly Scottsdale Paradise Valley ... Package . With at least 14 days advance notice, guests ...
(Date:6/19/2013)... 19, 2013 In 2011, the value ... 710 million. Generic drugs form the largest sector, accounting ... The pharmaceutical industry is a significant contributor to the ... country’s GDP. Approximately 50% of the total domestic chemical ... industry. Hemofarm, Galenika and Zdravlje Actavis are key participants ...
Breaking Medicine News(10 mins):Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 3Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 4Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 5Health News:Effective Environmental Services Launch New Websites to Serve Customers 2Health News:Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers 2Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 2Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 3Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 4Health News:Serbian Pharmaceutical Market Scrutinized by CUBE in Topical Report Now Available at MarketPublishers.com 2
... its growing family of CCRCs with expansion into ... POINT, Pa., June 2 ACTS Retirement-Life,Communities, a ... has completed its acquisition of Carlton Cove, a,continuing ... will be renamed Magnolia Trace and become the ...
... Imagine being able to communicate,your practice,s message to ... practice growth and development. That is the focus of ... parent company of JG Pads, a pharmaceutical sales,support company ... United States since 1993. Because of its success, MarketHATCH ...
... Drinking water disinfected by chlorine while pregnant may increase ... palate or major brain defects, according to a study ... Health. , This finding, based on an analysis ... that links by-products of water chlorination to three specific ...
... June 2 Isis,Pharmaceuticals, Inc. (Nasdaq: ISIS ... oncology drugs were highlighted during the American,Society of ... positive activity that supports the continuation of clinical,development, ... very high doses.,Results from Eli Lilly,s Phase 1 ...
... June 2 Kent Bottles, MD, has been,named ... (ICSI)., Dr. Bottles is a board-certified pathologist ... extensive experience in integrated,healthcare delivery systems, research, academia, ... companies., "Dr. Bottles, selection came after an ...
... American Oriental,Bioengineering (NYSE: AOB ) today announced ... repurchase program for the repurchase of up to ... Purchases under this program may be made, from ... transactions, and accelerated stock,repurchase transactions or otherwise, as ...
Cached Medicine News:Health News:ACTS Retirement-Life Communities Completes Carlton Cove Acquisition 2Health News:Ohio Company to Debut Turnkey Marketing Material During Florida National Dental Convention 2Health News:Is tap water safe for expectant mothers? 2Health News:Isis' Partners Present Clinical Data on Antisense Drugs at the American Society of Clinical Oncology 2Health News:Isis' Partners Present Clinical Data on Antisense Drugs at the American Society of Clinical Oncology 3Health News:Isis' Partners Present Clinical Data on Antisense Drugs at the American Society of Clinical Oncology 4Health News:Dr. Kent Bottles Named ICSI President 2Health News:American Oriental Bioengineering Announces US$75 Million Share Repurchase Program 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: